<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Schulz, Stefanie</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ISAR-REACT 3A: Low-Dose UFH Better for Elective PCI</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">Unfractionated heparin, at a dose of 100 U/kg, is preferable to standard higher-dose treatment in patients who are undergoing elective percutaneous coronary intervention, according to new findings from the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment 3A [ISAR-REACT 3A; NCT00735280] trial.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>